Skip to main content
Fig. 5 | Experimental Hematology & Oncology

Fig. 5

From: Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Fig. 5

Dysregulation of metabolic pathways contributes to the cytotoxicity of chidamide against LSC-like cells. A Immunobloting analysis of the levels of mTOR and the phosphorylation of AKT (p-AKT) in chidamide-treated CD34+CD38− KG1α and kasumi-1 cells. Assessment of the uptake levels of glutamine (B) and glucose (C) in CD34+CD38− KG1α and kasumi cells treated with designated concentrations of chidamide. D Analysis of the relative NADP + /NADPH ratio in CD34+CD38− KG1α and kasumi-1 cells exposed to chidamide. E, F Quantification of the cell viability of CD34+CD38− KG1α and kasumi-1 cells treated as described in Fig. 5B in the presence of the culture medium with or without glutamine deprivation. G The top 10 altered signaling pathways affected by the combination of apatinib and chidamide in the RNA sequencing assasy

Back to article page